• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis.

作者信息

Taher Ali T, Origa Raffaella, Perrotta Silverio, Kouraklis Alexandra, Belhoul Khawla, Huang Vicky, Han Jackie, Bruederle Andreas, Bobbili Priyanka, Duh Mei Sheng, Porter John B

机构信息

Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

Ospedale Pediatrico Microcitemico 'A Cao', University of Cagliari, Cagliari, Italy.

出版信息

Am J Hematol. 2019 Apr;94(4):E96-E99. doi: 10.1002/ajh.25408. Epub 2019 Jan 31.

DOI:10.1002/ajh.25408
PMID:30663129
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6590223/
Abstract
摘要

相似文献

1
Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis.患者报告结局对ECLIPSE试验中地拉罗司薄膜包衣片和分散片制剂治疗效果的影响：一项事后中介分析。
Am J Hematol. 2019 Apr;94(4):E96-E99. doi: 10.1002/ajh.25408. Epub 2019 Jan 31.
2
Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.优化依赖输血的地中海贫血和低危骨髓增生异常综合征患者的地拉罗司治疗管理。
Eur J Haematol. 2018 Sep;101(3):272-282. doi: 10.1111/ejh.13111. Epub 2018 Jul 27.
3
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.一项随机 II 期研究中接受地拉罗司分散片治疗的输血依赖型贫血患者的报告结局。
Health Qual Life Outcomes. 2018 Nov 19;16(1):216. doi: 10.1186/s12955-018-1041-5.
4
Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study.转铁蛋白超负荷的儿科患者应用地拉罗司颗粒和分散片的依从性和临床获益：一项随机、开放标签、多中心、二期研究。
Haematologica. 2024 May 1;109(5):1413-1425. doi: 10.3324/haematol.2023.283133.
5
Deferasirox film-coated tablet-associated ulcerative colitis: An emerging pattern in thalassemia patients?地拉罗司薄膜衣片相关性溃疡性结肠炎：地中海贫血患者中一种新出现的模式？
Br J Haematol. 2024 Aug;205(2):719-721. doi: 10.1111/bjh.19558. Epub 2024 May 23.
6
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.去铁斯若新的薄膜包衣片新剂型在β地中海贫血或低危骨髓增生异常综合征患者中耐受性良好：随机II期ECLIPSE研究结果
Am J Hematol. 2017 May;92(5):420-428. doi: 10.1002/ajh.24668. Epub 2017 Feb 18.
7
Predicting serum ferritin levels in patients with iron overload treated with the film-coated tablet of deferasirox during the ECLIPSE study.在ECLIPSE研究中预测接受地拉罗司薄膜包衣片治疗的铁过载患者的血清铁蛋白水平。
Am J Hematol. 2019 Jan;94(1):E15-E17. doi: 10.1002/ajh.25322. Epub 2018 Nov 15.
8
Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia.患者对地拉罗司薄膜包衣与分散片制剂的偏好：一项在地中海贫血患者中进行的序贯设计 2 期研究。
Ann Hematol. 2023 Aug;102(8):2039-2049. doi: 10.1007/s00277-023-05240-3. Epub 2023 May 25.
9
Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring.针对治疗调整的地拉罗司制剂的药理学和临床评估。
Sci Rep. 2021 Jun 15;11(1):12581. doi: 10.1038/s41598-021-91983-w.
10
Deferasirox-induced liver injury and Fanconi syndrome in a beta-thalassemia major male.地拉罗司致肝损伤及范可尼综合征 1 例：β 地中海贫血男性患者
BMJ Case Rep. 2020 Jul 9;13(7):e234542. doi: 10.1136/bcr-2020-234542.

引用本文的文献

1
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.改善镰状细胞病或地中海贫血患者铁螯合治疗依从性的干预措施。
Cochrane Database Syst Rev. 2023 Mar 6;3(3):CD012349. doi: 10.1002/14651858.CD012349.pub3.

本文引用的文献

1
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.去铁斯若新的薄膜包衣片新剂型在β地中海贫血或低危骨髓增生异常综合征患者中耐受性良好：随机II期ECLIPSE研究结果
Am J Hematol. 2017 May;92(5):420-428. doi: 10.1002/ajh.24668. Epub 2017 Feb 18.
2
Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.药物依从性对去铁胺治疗骨髓增生异常综合征输血性铁过载疗效的影响。
J Clin Pharm Ther. 2016 Feb;41(1):59-63. doi: 10.1111/jcpt.12348. Epub 2016 Jan 18.
3
Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial.地拉罗司治疗β-地中海贫血铁过载患者的疗效满意度和便利性提高：ESCALATOR 试验结果。
Acta Haematol. 2010;123(4):220-5. doi: 10.1159/000313447. Epub 2010 Apr 27.
4
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.地拉罗司或去铁胺治疗β地中海贫血患者铁过载期间患者报告结局的前瞻性评估。
Clin Ther. 2007 May;29(5):909-917. doi: 10.1016/j.clinthera.2007.05.007.
5
Estimating the proportion of treatment effect explained by a surrogate marker.估计由替代标志物解释的治疗效果比例。
Stat Med. 1997 Jul 15;16(13):1515-27. doi: 10.1002/(sici)1097-0258(19970715)16:13<1515::aid-sim572>3.0.co;2-1.